245 related articles for article (PubMed ID: 37901249)
41. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
42. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
[TBL] [Abstract][Full Text] [Related]
44. Rituximab in the management of juvenile pemphigus foliaceus.
Loh TY; Paravar T
Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633733
[TBL] [Abstract][Full Text] [Related]
45. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
Fortuna G; Calabria E; Ruoppo E; Adamo D; Aria M; Amato M; Mignogna MD
J Oral Pathol Med; 2020 Jan; 49(1):91-95. PubMed ID: 31420993
[TBL] [Abstract][Full Text] [Related]
46. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
Sami N; Qureshi A; Ruocco E; Ahmed AR
Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
[TBL] [Abstract][Full Text] [Related]
47. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
[TBL] [Abstract][Full Text] [Related]
48. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
49. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.
Porro AM; Hans Filho G; Santi CG
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):20-32. PubMed ID: 31166407
[TBL] [Abstract][Full Text] [Related]
50. The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation.
Arduino PG; Broccoletti R; Carbone M; Conrotto D; Sciannameo V; Gambino A; Cabras M; Carrozzo M; Baldovino S
J Oral Pathol Med; 2020 Feb; 49(2):177-180. PubMed ID: 31804741
[TBL] [Abstract][Full Text] [Related]
51. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1073-9. PubMed ID: 21143649
[TBL] [Abstract][Full Text] [Related]
52. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Doukaki S; Platamone A; Alaimo R; Bongiorno MR
J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
[TBL] [Abstract][Full Text] [Related]
53. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.
Cummins DL; Mimouni D; Anhalt GJ; Nousari CH
J Am Acad Dermatol; 2003 Aug; 49(2):276-80. PubMed ID: 12894077
[TBL] [Abstract][Full Text] [Related]
54. Treatment of pemphigus vulgaris: part 2 - emerging therapies.
Yanovsky RL; McLeod M; Ahmed AR
Expert Rev Clin Immunol; 2019 Oct; 15(10):1061-1071. PubMed ID: 31575295
[No Abstract] [Full Text] [Related]
55. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus.
Sami N; Bhol KC; Ahmed AR
Clin Immunol; 2002 Nov; 105(2):192-8. PubMed ID: 12482393
[TBL] [Abstract][Full Text] [Related]
56. Pemphigus vulgaris: approach to treatment.
Sinha AA; Hoffman MB; Janicke EC
Eur J Dermatol; 2015 Apr; 25(2):103-13. PubMed ID: 25547117
[TBL] [Abstract][Full Text] [Related]
57. Epidemiological and clinical characteristics of patients with pemphigus treated in Białystok in 2001-2018.
Serwin AB; Flisiak I
Przegl Epidemiol; 2020; 74(3):457-465. PubMed ID: 33570343
[TBL] [Abstract][Full Text] [Related]
58. Rituximab/IVIG in pemphigus - a 10-year study with a long follow-up.
Hamadah I; Chisti MA; Haider M; Binamer Y; Alajlan S; Aleyouni Y; Alfadley A
J Dermatolog Treat; 2019 Mar; 30(2):170-175. PubMed ID: 29889591
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.
Lemieux A; Maho-Vaillant M; Golinski ML; Hébert V; Boyer O; Calbo S; Candon S; Joly P
JAMA Dermatol; 2022 Aug; 158(8):893-899. PubMed ID: 35731529
[TBL] [Abstract][Full Text] [Related]
60. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
Ahmed AR; Shetty S
Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
